4 days Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates Zacks

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?